Upstream Biosciences Inc. Appoints University of British Columbia
Dean of Pharmaceutical Sciences Robert Sindelar to Scientific
Advisory Board
VANCOUVER, BC -- (MARKET WIRE) -- 06/14/2006 -- Upstream Biosciences
Inc. (OTCBB: UPBS) ("Upstream" or "the Company"), an emerging leader
in the field of genetic diagnostics for cancer and the prediction of
drug response, has announced today the appointment of Dr. Robert D.
Sindelar to its scientific advisory board. Dr. Sindelar is Professor
and Dean of the Faculty of Pharmaceutical Sciences at The University
of British Columbia.
Dr. Sindelar's expertise lies in medicinal chemistry, computer-aided
drug discovery and design, pharmaceutical biotechnology, and
creating opportunities to integrate innovation into the health care
system. He maintained an active research program that focused on the
human immune system and drug design for related diseases. This work
resulted in more than $14 million (US$) in extramural funding as
Principle (PI) and Co-PI Investigator, about 60 refereed journal
articles, six U.S. patents, several foreign patents and over 100
scientific and professional presentations. He serves as a member of
the editorial boards of various scientific journals, including The
APhA Biotechnology Initiative, Current Medicinal Chemistry, Current
Patents in Infectious Diseases, Medicinal Chemistry, and the journal
IDrugs: The Investigational New Drug Journal. Besides having co-
edited a popular textbook on pharmaceutical biotechnology, which has
been translated into several languages, Dr. Sindelar is the
recipient of several School and University-wide teaching honors. In
addition to his leadership role in the Faculty, Dr. Sindelar
continues to teach in the professional undergraduate curriculum in
several courses. He has been active in promoting the profession of
pharmacy, the BC biotechnology community and life sciences research
with numerous government and health care stakeholders at the
national and local levels. He currently sits on the Council of The
College of Pharmacists of British Columbia, serves on the Board of
Directors of BC Biotech and serves on other scientific advisory
boards.
"Dr. Sindelar's extensive experience in the pharmaceutical sciences
coupled with his knowledge of the healthcare system could help
accelerate our research," says Upstream CEO Joel Bellenson. "We are
pleased to add another prominent member of the healthcare community
to our team."
"Genetics will play an ever-increasing role in explaining, and
eventually predicting, the effectiveness of drug therapy," says Dr.
Sindelar. "A patient's genetic profile can have a significant impact
on drug response, both the desired effect, but also adverse drug
reactions."
Upstream is developing diagnostic tests that may aid in the early
detection of cancer by identifying individuals with disease
susceptibility. Upstream is also developing diagnostic tests that
may determine whether a drug will be useful or harmful to an
individual patient based on their genetic profile. According to the
Journal of the American Medical Association, each year 100,000
people die in the United States due to adverse reactions to
prescription drugs.
About Upstream Biosciences Inc.
Upstream Biosciences Inc. is an emerging leader in the field of
genetic diagnostics for cancer and the prediction of drug response
founded in 2004. Upstream discovers, develops, and licenses genetic-
based diagnostics for cancer susceptibility and drug response.
Upstream's proprietary data mining pipeline enables it to locate and
analyze genetic variations in the regions of DNA 'upstream' of the
gene, the 'gene switches,' which control the quantities and timing
of expression of the genes and proteins important to disease and
drug response.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements," as that
term is defined in Section 27A of the United States Securities Act
of 1933, as amended, and Section 21E of the United States Securities
Exchange Act of 1934, as amended. Statements in this press release,
which are not purely historical, are forward-looking statements and
include any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking statements
include, among others, the expectation and/or claim, as applicable,
that: (i) the Company may become an emerging leader in the field of
diagnostics for cancer and the prediction of drug response; (ii) Dr.
Sindelar can help the Company discover effective diagnostic tools;
(iii) genetic research could have a major impact in the field of
diagnostics; (iv) Dr. Sindelar may assist the Company in discovering
new diagnostic markers; (v) the Company is developing diagnostic
tests that may aid in the early detection of cancer by identifying
individuals with disease susceptibility; (vi) the Company is
developing diagnostic tests that may determine whether a drug will
be useful or harmful to an individual patient based on their genetic
profile; (vii) the Company may discover, develop and license its
genetic based diagnostics for cancer susceptibility and drug
response; and (viii) the Company's data mining pipeline may enable
the Company to locate and analyze genetic variations in the regions
of DNA which control the quantities and timing of expression of the
genes and proteins important to disease and drug response.
Actual results could differ from those projected in any forward-
looking statements due to numerous factors. Such factors include,
among others: (i) the risk that the Company does not execute its
business plan; (ii) the inability of the Company to keep pace with
technological advancements in the field of genetic diagnostics;
(iii) the Company's inability to adequately protect its intellectual
property or the Company's inadvertent infringement of third party
intellectual property; (iv) the Company not being able to retain key
employees; (v) competitors providing better or cheaper products and
technologies; (vi) markets for the Company's products not developing
as expected; (vii) the Company's inability to finance its operations
or growth; (viii) inability to obtain all necessary government and
regulatory approvals; and (ix) the inability to effectively market
and commercialize the Company's technologies, including the
establishment of viable relationships with third parties. These
forward-looking statements are made as of the date of this news
release and the Company assumes no obligation to update the forward-
looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Although the Company believes that the beliefs, plans, expectations
and intentions contained in this press release are reasonable, there
can be no assurance those beliefs, plans, expectations, or
intentions will prove to be accurate. Investors should consider all
of the information set forth herein and should also refer to the
risk factors disclosed in the Company's periodic reports filed from
time-to-time with the Securities and Exchange Commission and
available at www.sec.gov.
Distributed by Filing Services Canada and retransmitted by Market
Wire
---------------------------------------------------------------------
-----------
For more information, please contact:
Samantha Haynes
1-800-539-0289
Email Contact
SOURCE: Upstream Biosciences Inc.
------------------------ Yahoo! Groups Sponsor --------------------~-->
Great things are happening at Yahoo! Groups. See the new email design.
http://us.click.yahoo.com/TISQkA/hOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
